Latest Breaking News On - Roberto pellicciari - Page 2 : comparemela.com

TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis

INT-787 is a selective next generation FXR agonist invented by TES Pharma and licensed to Intercept Pharmaceuticals INT-787 has shown strong anti-fibrotic and anti-inflammatory effects

United statesPharma srlAntimo gioielloJanet robertsonAntonio macchiaruloRoberto pellicciariDepartment of chemistryDrug technologies of the university perugiaIntercept pharmaceuticalsIntercept pharmaceuticals incMedicinal chemistry research groupSevere alcohol associated hepatitisFarnesoidx receptorAmerican associationLiver diseasesDrug technologies

B Riley Financial Sticks to Its Hold Rating for Intercept Pharma (ICPT)

B Riley Financial Sticks to Its Hold Rating for Intercept Pharma (ICPT)
markets.co - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from markets.co Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesMarke pruzanskiMayank mamtaniArrowhead pharmaceuticalsIntercept pharmaceuticals incSpectrum pharmaceuticalsMadrigal pharmaceuticalsIntercept pharmaResearch reportRoberto pellicciari